PharmaFocus Today – Page 11 – media

Changes in the Core of Medical Insurance Negotiations

After several years of practice, the thinking of medical insurance negotiations has completely changed. Drug prices still need to be controlled, and exchanging volume for price is the unshirkable responsibility of the Medical Insurance Bureau as a large buyer. However, the tone of the negotiations has changed. In the past few years, the Medical Insurance Bureau emphasized “soul bargaining”; but in this year’s medical insurance negotiations, the official tone of the Medical Insurance Bureau has become “two-way running.” “Going in both directions” means no longer just pursuing low prices, but negotiating with a reasonable price and stable expectations. For medical insurance, including more high-quality drugs through negotiations with pharmaceutical companies is to strive for the maximum benefits for insured persons on the basis of maintaining the stable operation of the fund; and for pharmaceutical companies, entering medical insurance can usually show significant benefits. By increasing sales, the commercialization process can ...
- Source: drugdu
- 73
- December 3, 2024
21 billion, the medical device giant officially announced a big move

Recently, Cardinal Health announced a major financial move, announcing the successful public offering of $2.9 billion in senior notes. The relevant details have been disclosed in the 8-K filing submitted to the U.S. Securities and Exchange Commission. On November 11, Cardinal announced that it would acquire GI Alliance and Diabetes Supply Group for $3.9 billion (approximately RMB 28.2 billion) to expand its business layout in the professional medical and home healthcare fields. Cardinal said that the funds raised from the note issuance will be used in part to provide financial support for its planned acquisition of a majority stake in GI Alliance Holdings, LLC and Advanced Diabetes Supply Group, covering related fees and expenses. The remaining funds will be used for general corporate purposes until they can be used for acquisitions. It is reported that the notes issued by Cardinal this time cover different maturities and interest rates, including $500 ...
- Source: drugdu
- 73
- December 3, 2024
AstraZeneca, who will replace Wang Lei?

Recently, AstraZeneca announced an important personnel change on its official website, appointing Bob Li, an Asian scientist at Memorial Sloan-Kettering Cancer Center (MSK) in the United States, as the new head of global medical affairs for oncology. He will report directly to David Fredrickson, head of AstraZeneca’s oncology business unit. Although Mr. Li is 42 years old and his position has not yet reached the company’s senior management, his Chinese identity and background have attracted widespread public attention. Mr. Li, an Australian-Chinese born in Shanghai, has served as a physician ambassador for China and the Asia-Pacific region at MSK, and is also a senior fellow in global public health at the China Analysis Center of the Asia Society Policy Institute. Mr. Li’s career shows that he has established cooperative relationships with many medical organizations in China, including a cooperative project between MSK and the China Thoracic Tumor Research Collaborative Group. ...
- Source: drugdu
- 69
- December 2, 2024
The first nasal “dry eye” treatment drug is approved for marketing

On November 27, Jixing Pharmaceutical announced that the National Medical Products Administration has approved the new drug application for its ophthalmic product, Varenicline tartrate nasal spray, to increase the tear secretion of patients with dry eyes. According to the data of “Chinese Dry Eye Expert Consensus (2020)”, the current incidence of dry eye in my country is about 21%-30%. Dry eye is closely related to excessive eye use, wearing contact lenses and other lifestyle habits. Common symptoms include dry eyes, foreign body sensation, burning sensation, itchy eyes, pain, red eyes, visual fatigue, blurred vision, and vision fluctuations. Natural tear deficiency and tear film instability are the core mechanisms of dry eye. Varenicline tartrate nasal spray is a highly selective acetylcholine receptor agonist that promotes natural tear secretion to stabilize the tear film by activating the trigeminal parasympathetic pathway. The approval data is based on the results of three key clinical ...
- Source: drugdu
- 76
- December 2, 2024
CAR-T, a special medicine for tumors, is out of the medical insurance again

On November 28, the results of the 2024 medical insurance catalog negotiation were announced: 91 new drugs were added to the national medical insurance drug catalog, of which 89 were included by negotiation/bidding, and another 2 were selected in the national centralized procurement. After checking the medical insurance drugs, Sina Medical Editor found that the 4 CAR-T products that had passed the preliminary review did not appear on the list. Regarding “Why is it difficult for CAR-T to enter the medical insurance catalog”, at the press conference held by the National Medical Insurance Administration on the morning of November 28, Wang Guodong, deputy director of the Medical Insurance Management Center of the National Medical Insurance Administration, introduced that some expensive cell and gene therapy drugs have been launched one after another, and it is difficult to fully support them by relying solely on basic medical insurance. At present, the National ...
- Source: drugdu
- 56
- December 2, 2024
CanSino Biologics’ Quadrivalent Meningococcal Conjugate Vaccine Age Extension Application Accepted by the National Medical Products Administration

According to CanSino’s official WeChat account, the supplemental application for CanSino Biologics’ ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier), referred to as “Mankexin®,” has been accepted by the National Medical Products Administration (NMPA) and a notice of acceptance has been issued. This supplemental application expands the age range for the use of Mankexin® from “3 months to 3 years (47 months) children” to “3 months to 6 years (83 months) children.” Mankexin® received approval from the NMPA on December 29, 2021. https://finance.eastmoney.com/a/202411263251192857.html
- Source: drugdu
- 68
- December 2, 2024
400 million antibacterial injections, Huiyu Pharmaceutical has won the first imitation!

On November 27th, according to the official website of NMPA, Sichuan Huiyu Pharmaceutical’s application for the marketing of four types of generic drugs – morpholine nitrate sodium chloride injection – was approved and deemed to have passed the consistency evaluation, becoming the first domestic generic drug. At present, only Jiangsu Haosen Pharmaceutical Co., Ltd. has been approved as a new drug Class 1.1 for the injection of sodium methoxam and sodium chloride. There are currently no other companies approved for Class 4 generic drugs in China. Morpholinenidazole sodium chloride injection is mainly used for antibacterial and anti-inflammatory purposes. It belongs to the third generation of nitroimidazole antibacterial drugs, and the national medical insurance class B, which is used to treat pelvic inflammation, appendicitis and other infectious diseases. It has a strong antibacterial effect on anaerobic bacteria and is widely used in clinical practice. According to the Moen Pharmaceutical Database, the ...
- Source: drugdu
- 70
- November 30, 2024
China Resources Pharmaceutical Commercial and Pfizer officially sign a strategic cooperation agreement

On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. 01. China Resources wins commercial promotion authorization for four heavyweight cancer drugs On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. According to the “Pharmaceutical Representative”, the cooperation will officially begin on December 1st. Employees affected by this cooperation will go to Shanghai for offline communication, and the final employee placement will be completed by the end of next month. The four drugs involved in this transaction have been in the Chinese market for many years, namely AROMASIN, IBRANCE, Pharmarubicin RD, and XALKORI. Among them, Famax was ...
- Source: drugdu
- 93
- November 30, 2024
The first national pharmaceutical public REITs, leading the new development of the pharmaceutical industry

Real estate securitization (REITs) brings about the “three new” trends On November 7th, at the sub forum of the 3rd Green Finance Forum in 2024, Jiuzhou Tong, a leading pharmaceutical circulation enterprise, shared the “three new” trends brought by real estate securitization (REITs). What are the ‘three new’? According to Su Xiling, Deputy General Manager of Jiuzhou Tong Pharmaceutical Group Co., Ltd. and Head of Jiuzhou Production and Investment, firstly, there is a new financing model. REITs, as innovative, non stock, non debt equity financing, provide new financing channels for enterprises, which is conducive to building new production and financing platforms and providing new investment products for the capital market; Secondly, there is a new driving force for development. After the successful issuance of Kyushu Tong’s public REITs, about 80% of the raised funds will be used for infrastructure construction in areas such as pharmaceutical warehousing; The third is the ...
- Source: drugdu
- 62
- November 30, 2024
China Resources Group announces heavyweight cooperation

On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. 01 China Resources wins commercial promotion authorization for four heavyweight cancer drugs On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. According to the “Pharmaceutical Representative”, the cooperation will officially begin on December 1st. Employees affected by this cooperation will go to Shanghai for offline communication, and the final employee placement will be completed by the end of next month. picture The four drugs involved in this transaction have been in the Chinese market for many years, namely AROMASIN, IBRANCE, Pharmarubicin RD, and XALKORI. Among them, Famax ...
- Source: drugdu
- 58
- November 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.